Correlation Between Ibio and Novavax
Can any of the company-specific risk be diversified away by investing in both Ibio and Novavax at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ibio and Novavax into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Ibio Inc and Novavax, you can compare the effects of market volatilities on Ibio and Novavax and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ibio with a short position of Novavax. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ibio and Novavax.
Diversification Opportunities for Ibio and Novavax
Very good diversification
The 3 months correlation between Ibio and Novavax is -0.43. Overlapping area represents the amount of risk that can be diversified away by holding Ibio Inc and Novavax in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Novavax and Ibio is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ibio Inc are associated (or correlated) with Novavax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Novavax has no effect on the direction of Ibio i.e., Ibio and Novavax go up and down completely randomly.
Pair Corralation between Ibio and Novavax
Given the investment horizon of 90 days Ibio Inc is expected to generate 1.62 times more return on investment than Novavax. However, Ibio is 1.62 times more volatile than Novavax. It trades about 0.02 of its potential returns per unit of risk. Novavax is currently generating about 0.02 per unit of risk. If you would invest 1,120 in Ibio Inc on August 31, 2024 and sell it today you would lose (857.00) from holding Ibio Inc or give up 76.52% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 99.79% |
| Values | Daily Returns |
Ibio Inc vs. Novavax
Performance |
| Timeline |
| Ibio Inc |
| Novavax |
Ibio and Novavax Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Ibio and Novavax
The main advantage of trading using opposite Ibio and Novavax positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ibio position performs unexpectedly, Novavax can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novavax will offset losses from the drop in Novavax's long position.| Ibio vs. Jaguar Animal Health | Ibio vs. GeoVax Labs | Ibio vs. Ocugen Inc | Ibio vs. Tonix Pharmaceuticals Holding |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Complementary Tools
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |